With over 30 years of clinical excellence in MS, Biogen is a leader in multiple sclerosis (MS) research. Biogen continues its commitment to patients through ongoing research, solutions and services to support unmet needs in the management of MS. Biogen currently has the broadest MS portfolio in the industry with products that help treat across the spectrum of relapsing forms of MS. Through affordability programmes, such as Patient Access Schemes, we are committed to continuing to improve access to products for patients who need them.